**请收集一下大家的简介**

格式(英文)：

职工的格式：

<h3> Dr. Danqi Chen </h3>

<p> Dr. Danqi Chen earned her Bachelor's degree from the School of Pharmacy at Fudan University and completed an integrated Master's and Ph.D. program at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), specializing in medicinal chemistry. Following her graduation, she joined SIMM as a researcher and has been engaged in drug discovery and development for many years.

With extensive experience in drug design and development, Dr. Chen has published multiple SCI-indexed papers as first or corresponding author in renowned journals, including Acta Pharmaceutica Sinica B, Journal of Medicinal Chemistry, Acta Pharmacologica Sinica, and European Journal of Medicinal Chemistry. She has participated in and led collaborative projects with pharmaceutical companies such as GSK and Lundbeck, and has served as Principal Investigator (PI) for the National Natural Science Foundation of China (NSFC) Youth Program, sub-projects under China's National Major Science and Technology Projects, and the CAS Strategic Priority Research Program. </p>

<h3> Dr. Tongchao Liu, Associate Research Fellow </h3>

<p> Dr. Liu is currently an Associate Research Fellow in Prof. Xiong’s lab at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He obtained his Ph.D. degree majoring in medicinal chemistry from Shenyang Pharmaceutical University in 2019. Specifically, He participated in a joint training program at the Shanghai Institute of Materia Medica from 2014 to 2019 (Advisor: Bing Xiong). His research has primarily focused on the structure-based drug design and chemical synthesis of novel and target-specific molecules for the treatment of cancers as well as other human diseases. He has obtained the financial support from the National Natural Science Foundation of China, the China Postdoctoral Science Foundation and the Shanghai Post-doctoral Excellence Program. Besides, he was also involved in the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” and the Strategic Priority Research Program of the CAS, et al. Up to now, he has published more than 20 peer-reviewed papers and applied for 14 patents. Through the research of these projects, he has gained extensive experience in drug discovery. Dr. Liu will continue his efforts to integrate transdisciplinary approaches to further advance the understanding of diseases and to develop novel therapeutics.</p>

<h3>Ms Danyan Cao</h3>

<p>Ms Cao graduated with a master's degree in microbiology in 2007 and joined the Shanghai Institute of Materia Medica in the same year. At the beginning, she worked as an assistant researcher for the chemical colleagues to complete the vitro activity tests and cell function tests of compounds. Later, she began to focus on epigenetic proteins, such as the bromodomain-containing proteins and the histone demethylase LSD1. She is currently focusing on phage-displayed cyclic peptides and is committed to discovering regulatory cyclic peptides for protein-protein interactions.</p>

<h3> Ms Zhiyan Du </h3>

<p> Research Scientist. Specialized in structure biology. </p>

<h3>Ms Lin Chen</h3>

<p>Research Scientist. Specialized in mass spectrometry screening and analysis.</p>

<h3>Ms Ying Wang</h3>

<p>Research Scientist. Specialized in structure biology, Mass Spectrometry Screening and Analysis.</p>

<h3>Yanlian Li</h3>

<p> Research Scientist. She is primarily engaged in the development and application of advanced computational techniques within the realm of drug discovery. By integrating interdisciplinary approaches that combine chemistry, biology, and computer science, that aims to accelerate the drug discovery pipeline. </p>

<h3> Ting Yu </h3>

<p> Engaging in chemical synthesis. </p>

学生的格式：

<h3>Junjie Zhang</h3>

<p>Graduate Student (2019-2025). Working on the development of small molecule targeting multiple protein post-translational modification enzymes. </p>

<h3>Li Na </h3>

<p>Graduate Student (2019-2025). Working on innovative drug discovery programs focused on: (1) the design and optimization of selective Nav1.8 inhibitors for pain treatment, and (2) the development of novel reversible LSD1 inhibitors for targeted cancer therapy.</p>

<h3>Lingyu Song</h3>

<p>Graduate Student （2020-2025）. Working on discovering and modifying cyclic peptide drugs. Using phage display technology to develop large combinatorial libraries (> a billion variants) of peptides with diverse chemical linkers and efficiently screen for high-affinity ligands that can bind to targets of interest.</p>

<h3> Huanyu Xu</h3>

<p> Graduate student (2021-). Working on Design, Synthesis, and Biological Efficacy of P2X4 Receptor Inhibitors. </p>

<h3> Xinlong Shen </h3>

<p> Xinlong Shen is a graduate student at Shanghai Institute of Materia Medica (SIMM), UCAS, pursuing a Ph.D. in Medicinal Chemistry (2022-). He obtained the bachelor's degree in Pharmacy from East China University of Science and Technology (2018-2022). His primary research focuses on the design and synthesis of novel drug molecules, with a particular emphasis on GPCR-related studies. Utilizing structure/fragment based drug discovery and computer-aided drug design (CADD), to the design and chemical synthesis of novel small molecules. He has gained proficiency in organic synthesis methodologies, NMR, HPLC and MS, also has developed a preliminary understanding of molecular docking, molecular dynamics simulations, and pharmacophore modeling as part of computational drug design techniques.</p>

<h3> Wan Li </h3>

<p> Graduate student (2022-2025). Working on Design and synthesis of solid phase synthetic cyclic peptide library and cyclization crosslinking agent .</p>

<h3> Junyuan Wei </h3>

<p> Graduate student (2022-2025). Working on Design, synthesis, and biology of DDR inhibitors and degradation agents activity evaluation. </p>

<h3> Chong Shen </h3>

<p> Chong Shen is a graduate student at University of Chinese Academy of Sciences and joined the Xiong Lab at Department of Medicinal Chemistry, SIMM in 2023. He graduated from Chinese Pharmaceutical University in 2023 with a B.S. in Pharmacy. In Xiong Lab, he has learned the professional skills of drug design and chemical synthesis, and his current research focuses on the small-molecule drug discovery targeting GPCRs against cardiovascular disease.</p>

<h3> Yushan Zhou </h3>

<p> Graduate student(2023-2026). Master's student (Class of 2023) in the Bio-Pharmaceutical program at the Wuya Innovation College, Shenyang Pharmaceutical University. Her research focuses on the discovery of structural or fragment-based drugs targeting post-translational modifications of proteins. Currently, she is involved in the biosynthesis of Apelin receptor agonists and Mat2a inhibitors. </p>

<h3>Li Taoran</h3>

<p>Graduate student(2023-2026). Working on discovery of Small-Molecule Modulators Targeting the TRIM Family Proteins.Combining advanced protein purification techniques with X-ray crystallography, we aim to determine high-resolution three-dimensional structures of target proteins and their complexes. This structural insight allows us to decipher functional mechanisms, ligand interactions, and conformational changes critical to their biological roles. </p>

<h3> Ruyue Ren </h3>

<p> Graduate student(2023-2026). She obtained a bachelor's degree from Shenyang Pharmaceutical University (2019-2023), and is currently studying in Shanxi Medical University Master's degree. Currently, her research focuses on the structure/fragment-based drug discovery in protein post-translational modificaitons. </p>

<h3> Rong rong Pan </h3>

<p> Graduate student(2023-2026).working on predicting interaction between the molecule and the α4β7 target by computer-aided drug design techniques and potentially active compounds are synthesized. The most promising drug candidates were selected through in vitro and in vivo experiments, and their chemical structures were further optimized to improve efficacy, reduce toxicity and improve pharmacokinetic properties. </p>

<h3> ZiHeng Yang </h3>

<p> ZiHeng Yang is a graduate student in Bing Xiong’s Laboratory. He obtained a bachelor's degree from Shandong First Medical University (2019-2023), and is currently studying in Shenyang Pharmaceutical University master's degree. Currently, his research focuses on the structure/fragment-based drug discovery in protein post-translational modificaitons.

</p>

<h3> Shujuan Hu </h3>

<p> Shujuan Hu is a jointly cultivated postgraduate in Bing Xiong's Laboratory. She graduated with a Bachelor's degree in Pharmacy from the School of Pharmacy at Jiangxi Science and Technology Normal University（2020-2024）. Currently, she is pursuing a Master's degree at Xuzhou Medical University. And her research primarily focuses on the ubiquitin field. </p>

<h3> Weiliang Kuang </h3>

<p> Weiliang Kuang is a jointly cultivated postgraduate in Bing Xiong's Laboratory. He graduated from Zhejiang University of Technology (2020-2024) with a bachelor's degree. Currently, he is pursuing a master's degree at China Pharmaceutical University. His research focuses on important targets in cutting-edge epigenetics and conducts research on anti-tumor drugs.

</p>

<h3> Deliang Zhang </h3>

<p> Graduate Student(2024-2029) .</p>

如果自己有网页信息，可以提供超链接的网址

如愿意，可以提供照片